Company: GMP Unit University Hospital & Paracelsus Medical University, Salzburg
Job title: Head, Department of Transfusion Medicine & Director
Eva Rohde is Head of the Department of Transfusion Medicine at the University Hospital of the Paracelsus Medical University in Salzburg, Austria. She received her M.D. from the Karl-Franzens University of Graz, Austria in 1994, finished training in Transfusion Medicine in 2005 and spent several years in stem cell research as a postdoctoral fellow. Her research focuses on the application of stem cell-based therapies with special emphasis on their extracellular vesicles (MSCEVs).
Eva Rohde is Founding Member of the Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TRECS), Austria and Director and Qualified Person of the SCI-TReCS GMP Unit. The GMP Unit in Salzburg has achieved the pharmaceutical manufacturing authorization for MSC and MSC-EVs in 2015 and participated a clinical trial testing MSCs in multiple sclerosis. Recent effort is directed towards the preclinical characterization and the regulatory requirements for the clinical assessment and future application of stem-cell based products, including stromal cell-derived extracellular vesicles (EVs). In vitro and in vivo potency assays to define the immunomodulatory, neuroprotective, neuroregenerative and scarless healing support of MSC-EVs are currently developed. In a named patient use experiment, a single treatment of the inner ear with MSC-EVs was performed together with partners from the medical school Hanover and resulted in a very good safety outcome over a period of more than 12 months. Recently, her work at the GMP Unit Salzburg was highlighted in an outlook article in Nature
Clinical Potential of Unmodified Mesenchymal Stromal Cell- Derived EV Therapeutics 3:00 pm
Unravel how MSC-EVs may serve as potent anti-inflammatory, antiscarring and neuroprotective agents in various diseases The transition from EV research into clinical scale EV generation under good manufacturing practice is one of the bottlenecks for translational approaches and clinical development, not only in the EV field Another bottleneck is a sufficient characterization of EV therapeutics…Read more
day: Day One